No 'significant' benefit of favipiravir, umifenovir combination in Covid treatment: Glenmark

Glenmark had in May intimated the study to examine whether early administration of a combination of Favipiravir and Umifenovir enhances antiviral efficacy on Covid-19 patients. The company said that addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news